Li-Li Hong

Glycosylation switches spiramycin from an antibiotic to a hepatoprotective agent by targeting GSTP1.

Glycosylation commonly inactivates macrolide antibiotics, and the resulting glycosides are largely dismissed as inactive waste products. Whether such molecules retain hidden therapeutic potential remains underexplored. Here, we address this question using spiramycin I 2'-O-glucopyranoside as a proof-of-concept model. T...